Astonea Labs Limited has successfully incorporated a wholly-owned foreign subsidiary in the United States, marking a significant step in its international expansion strategy. The pharmaceutical company informed BSE Limited about the incorporation of Astonea LLC in Sheridan, Wyoming, USA, pursuant to the Certificate of Incorporation dated 25th January, 2026.

Subsidiary Details and Business Focus

Astonea LLC has been established to carry on business in pharmaceuticals, food supplements and cosmetics, which aligns with the parent company's existing operations. The subsidiary represents a strategic move to establish presence in the US market for these product categories.

Regulatory Compliance and Structure

The incorporation has been completed in full compliance with SEBI regulations, specifically under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Astonea Labs Limited holds 100% of the membership interests of Astonea LLC through cash subscription, establishing complete control over the subsidiary's operations.

Related Party Classification

As disclosed in the regulatory filing, Astonea LLC qualifies as a related party of Astonea Labs Limited due to its wholly-owned subsidiary status. The company has clarified that promoters and promoter group members have no direct interest in Astonea LLC, except through their existing shareholding in the parent company.

Strategic Implications

The establishment of Astonea LLC represents Astonea Labs Limited's commitment to expanding its pharmaceutical and related product operations internationally. Being a newly incorporated entity, Astonea LLC has no historical turnover data, but it positions the company to tap into the US market for pharmaceuticals, food supplements and cosmetics.

The incorporation was announced by Company Secretary and Compliance Officer Ankit Kapoor, ensuring proper disclosure to stakeholders and regulatory authorities as required under applicable SEBI circulars and listing regulations.

Astonea Labs Limited, a manufacturer and seller of cosmetics and pharmaceutical products, has announced its unaudited financial results for the half-year ended September 30, 2025, along with significant changes to its board of directors.

Financial Performance

The company reported a substantial increase in its revenue from operations for the half-year period:

All figures in Rs crores

The significant year-over-year growth of 40.20% in revenue demonstrates strong performance in the company's core business activities.

Board Appointments

Astonea Labs has appointed three new Non-Executive, Non-Independent Directors to its board, effective from November 10, 2025, subject to shareholder approval at the next Annual General Meeting:

1. Mr. Arun Kumar Tripathi (DIN: 08786789)

   • Age: 40 years
   • Qualification: Bachelor's degree in Pharmacy (B.Pharm)
   • Experience: Extensive experience in manufacturing pharmaceutical and cosmetic products

2. Mr. Pardeep Dalal (DIN: 02424111)

   • Age: 40 years
   • Qualification: Bachelor's degree in Arts
   • Experience: Professional experience in finance

3. Mr. Vikrant (DIN: 08686283)

   • Age: 39 years
   • Qualification: Degree in Dairy Science
   • Experience: Extensive professional experience in research and formulation of pharmaceutical and cosmetic products

These appointments are expected to bring diverse expertise to the company's board, potentially contributing to its growth and strategic direction.

Other Key Developments

• The board has authorized Ms. Pooja Singh to finalize a revised distribution agreement with Astonea One Private Limited, which may impact the company's distribution strategy.

• The company's board meeting on November 10, 2025, lasted from 12:30 PM to 1:45 PM.

Astonea Labs Limited, formerly known as Astonea Labs Private Limited, continues to focus on its core business of manufacturing and selling cosmetics and pharmaceutical products. The company's strong financial performance and strategic board appointments indicate its commitment to growth and corporate governance.

Investors and stakeholders will be keen to observe how these new appointments and the revised distribution agreement may influence the company's future performance and market position in the competitive pharmaceutical and cosmetics industry.